Inventor · disambiguated record
David L. Lewis
Also filed as: LEWIS DAVID · LEWIS DAVID L · LEWIS DAVID L M
44 granted patents·45 pending applications·803 citations·filing 2001–2025
98Inventor score
Files withEMPIRICO INC31ARROWHEAD PHARMACEUTICALS INC23ROZEMA DAVID B7ARROWHEAD MADISON INC6HOFFMANN LA ROCHE3
Top patents by PatentIndex Score
89 records- 0199US8313772B2Compositions for targeted delivery of siRNAROZEMA DAVID B·Filed 2011·Granted Nov 20, 2012·159 cites·25 claims
- 0298US8658211B2Polyconjugates for in vivo delivery of polynucleotidesROZEMA DAVID B·Filed 2012·Granted Feb 25, 2014·71 cites·23 claims
- 0398US8501930B2Peptide-based in vivo siRNA delivery systemROZEMA DAVID B·Filed 2011·Granted Aug 6, 2013·180 cites·18 claims
- 0498US8137695B2Polyconjugates for in vivo delivery of polynucleotidesROZEMA DAVID B·Filed 2007·Granted Mar 20, 2012·138 cites·27 claims
- 0596US11116778B2Prodrugs of ALOX-15 inhibitors and methods of using the sameEMPIRICO INC·Filed 2020·Granted Sep 14, 2021·9 cites·9 claims
- 0696US10130651B2RNAi Therapy for Hepatitis B Virus InfectionARROWHEAD PHARMACEUTICALS INC·Filed 2016·Granted Nov 20, 2018·22 cites·18 claims
- 0795US9932586B2Compositions and methods for inhibiting gene expression of LPAARROWHEAD PHARMACEUTICALS INC·Filed 2016·Granted Apr 3, 2018·9 cites·39 claims
- 0895US9796756B2Galactose cluster-pharmacokinetic modulator targeting moiety for siRNAARROWHEAD MADISON INC·Filed 2015·Granted Oct 24, 2017·24 cites·20 claims
- 0995US8802773B2In vivo polynucleotide delivery conjugates having enzyme sensitive linkagesROZEMA DAVID B·Filed 2013·Granted Aug 12, 2014·12 cites·22 claims
- 1095US8426554B2In vivo polynucleotide delivery conjugates having enzyme sensitive linkagesROZEMA DAVID B·Filed 2011·Granted Apr 23, 2013·47 cites·14 claims
- 1194US12188017B2Compositions and methods for inhibiting gene expression of alpha-1 antitrypsinARROWHEAD PHARMACEUTICALS INC·Filed 2022·Granted Jan 7, 2025·1 cites·12 claims
- 1294US11517584B2RNAi agents for Hepatitis B virus infectionARROWHEAD PHARMACEUTICALS INC·Filed 2021·Granted Dec 6, 2022·2 cites·58 claims
- 1394US11377658B2Oligonucleotides for treatment of angiopoietin like 4 (ANGPTL4) related diseasesEMPIRICO INC·Filed 2021·Granted Jul 5, 2022·2 cites·20 claims
- 1493US10662427B2Compositions and methods for inhibiting gene expression of LPAARROWHEAD PHARMACEUTICALS INC·Filed 2018·Granted May 26, 2020·6 cites·39 claims
- 1592US11590156B2RNAi agents for hepatitis B virus infectionARROWHEAD PHARMACEUTICALS INC·Filed 2020·Granted Feb 28, 2023·2 cites·37 claims
- 1692US10780108B2RNAi agents for Hepatitis B virus infectionARROWHEAD PHARMACEUTICALS INC·Filed 2017·Granted Sep 22, 2020·5 cites·67 claims
- 1792US9803205B2Compositions and methods for inhibiting gene expression of factor XIIARROWHEAD MADISON INC·Filed 2016·Granted Oct 31, 2017·9 cites·25 claims
- 1892US7101995B2Compositions and processes using siRNA, amphipathic compounds and polycationsMIRUS BIO CORP·Filed 2002·Granted Sep 5, 2006·34 cites·4 claims
- 1991US11384355B2Compositions and methods for inhibiting gene expression of alpha-1 AntiTrypsinARROWHEAD PHARMACEUTICALS INC·Filed 2019·Granted Jul 12, 2022·3 cites·23 claims
- 2090US10941404B2Treatment of angiopoietin like 7 (ANGPTL7) related diseasesEMPIRICO INC·Filed 2020·Granted Mar 9, 2021·2 cites·20 claims
- 2190US2025197861A1Compositions and methods for inhibiting gene expression of alpha-1 antitrypsinARROWHEAD PHARMACEUTICALS INC·Filed 2024·Application pending·0 cites
- 2289US10806750B2RNAi therapy for hepatitis B virus infectionARROWHEAD PHARMACEUTICALS INC·Filed 2018·Granted Oct 20, 2020·3 cites·9 claims
- 2388US10006025B2Compositions and methods for inhibiting gene expression of alpha-1 AntiTrypsinARROWHEAD MADISON INC·Filed 2015·Granted Jun 26, 2018·5 cites·25 claims
- 2488US9345775B2Compositions for targeted delivery of siRNAARROWHEAD MADISON INC·Filed 2015·Granted May 24, 2016·5 cites·27 claims
- 2587US10308941B2Compositions and methods for inhibiting gene expression of factor XIIARROWHEAD PHARMACEUTICALS INC·Filed 2017·Granted Jun 4, 2019·4 cites·26 claims
- 2686US10927373B2Compositions and methods for inhibiting gene expression of Hif2alphaARROWHEAD PHARMACEUTICALS INC·Filed 2018·Granted Feb 23, 2021·2 cites·20 claims
- 2786US9976141B2Compositions and methods for inhibiting gene expression of Hif2alphaARROWHEAD MADISON INC·Filed 2016·Granted May 22, 2018·5 cites·32 claims
- 2886US9011919B2Compositions for targeted delivery of siRNAROZEMA DAVID B·Filed 2012·Granted Apr 21, 2015·7 cites·22 claims
- 2986US2025115907A1Compositions and methods for inhibiting gene expression of lpaARROWHEAD PHARMACEUTICALS INC·Filed 2024·Application pending·0 cites
- 3084US9249179B2Galactose cluster-pharmacokinetic modulator targeting moiety for siRNAHADWIGER PHILIPP·Filed 2011·Granted Feb 2, 2016·10 cites·5 claims
- 3184US2025090559A1Prodrugs of alox-15 inhibitors and methods of using the sameEMPIRICO INC·Filed 2024·Application pending·0 cites
- 3283US9301990B2Small molecule conjugates for intracellular delivery of biologically active compoundsHOFFMANN LA ROCHE·Filed 2013·Granted Apr 5, 2016·2 cites·6 claims
- 3383US9107957B2Peptide-based in vivo siRNA delivery systemARROWHEAD MADISON INC·Filed 2013·Granted Aug 18, 2015·5 cites·14 claims
- 3480US9968647B2Small molecule conjugates for intracellular delivery of biologically active compoundsHOFFMANN LA ROCHE·Filed 2016·Granted May 15, 2018·1 cites·3 claims
- 3580US2023355651A1Rnai agents for hepatitis b virus infectionARROWHEAD PHARMACEUTICALS INC·Filed 2022·Application pending·0 cites
- 3679US7601367B2Compositions and processes using siRNA, amphipathic compounds and polycationsMIRUS BIO LLC·Filed 2004·Granted Oct 13, 2009·7 cites·6 claims
- 3779US2023355654A1Rnai therapy for hepatitis b virus infectionARROWHEAD PHARMACEUTICALS INC·Filed 2022·Application pending·0 cites
- 3879US2023248752A1Prodrugs of alox-15 inhibitors and methods of using the sameEMPIRICO INC·Filed 2023·Application pending·0 cites
- 3978US12258563B2Modified oligonucleotidesEMPIRICO INC·Filed 2023·Granted Mar 25, 2025·0 cites·19 claims
- 4078US9198947B2Small molecule conjugates for intracellular delivery of nucleic acidsHOFFMANN LA ROCHE·Filed 2013·Granted Dec 1, 2015·1 cites·5 claims
- 4178US2025228883A1Process to Inhibit or Eliminate Eosinophilic Diseases of the Airway and Related ConditionsEMPIRICO INC·Filed 2024·Application pending·0 cites
- 4276US12312586B2Treatment of MST1 related diseases and disordersEMPIRICO INC·Filed 2024·Granted May 27, 2025·0 cites·8 claims
- 4375US11666588B2Prodrugs of ALOX-15 inhibitors and methods of using the sameEMPIRICO INC·Filed 2021·Granted Jun 6, 2023·0 cites·20 claims
- 4475US2024392295A1Treatment of mst1 related diseases and disordersEMPIRICO INC·Filed 2024·Application pending·0 cites
- 4574US11840688B2Compositions and methods for inhibiting gene expression of Hif2alphaARROWHEAD PHARMACEUTICALS INC·Filed 2021·Granted Dec 12, 2023·0 cites·20 claims
- 4674US10858658B2Compositions and methods for inhibiting gene expression of factor XIIARROWHEAD PHARMACEUTICALS INC·Filed 2019·Granted Dec 8, 2020·0 cites·19 claims
- 4774US7781415B2Process for delivering sirna to cardiac muscle tissueROCHE MADISON INC·Filed 2004·Granted Aug 24, 2010·4 cites·16 claims
- 4874US2024287523A1Treatment of mst1 related diseases and disordersEMPIRICO INC·Filed 2024·Application pending·0 cites
- 4973US2023074280A1Treatment of thymic stromal lymphopoietin (tslp) related diseases by inhibition of long-form tslp transcriptsEMPIRICO INC·Filed 2022·Application pending·0 cites
- 5071US11534453B2RNAi therapy for hepatitis B virus infectionARROWHEAD PHARMACEUTICALS INC·Filed 2020·Granted Dec 27, 2022·0 cites·25 claims
Showing the top 50 of 89 patent records by PatentIndex Score.
Join the waitlist — get patent alerts
Get an alert when David L. Lewis files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →